{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,4]],"date-time":"2026-09-04T12:48:20Z","timestamp":1788526100534,"version":"build-2803163510"},"reference-count":128,"publisher":"Frontiers Media SA","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Front. Immunol."],"DOI":"10.3389\/fimmu.2014.00380","type":"journal-article","created":{"date-parts":[[2014,8,22]],"date-time":"2014-08-22T06:15:19Z","timestamp":1408688119000},"source":"Crossref","is-referenced-by-count":55,"title":["Visceral Leishmaniasis: Advancements in Vaccine Development via Classical and Molecular Approaches"],"prefix":"10.3389","volume":"5","author":[{"given":"Sumit","family":"Joshi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Keerti","family":"Rawat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Narendra Kumar","family":"Yadav","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vikash","family":"Kumar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohammad Imran","family":"Siddiqi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anuradha","family":"Dube","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2014,8,22]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"873","DOI":"10.1038\/nrmicro1748","article-title":"Visceral leishmaniasis: what are the needs for diagnosis, treatment and control?","volume":"5","author":"Chappuis","year":"2007","journal-title":"Nat Rev Microbiol"},{"issue":"10","key":"B2","doi-asserted-by":"publisher","first-page":"1662","DOI":"10.3201\/eid1810.111083","article-title":"Visceral leishmaniasis in rural Bihar, India","volume":"18","author":"Hasker","year":"2012","journal-title":"Emerg Infect Dis"},{"key":"B3","doi-asserted-by":"publisher","first-page":"692","DOI":"10.1038\/nrmicro981","article-title":"Leishmaniasis","volume":"2","author":"Desjeux","year":"2004","journal-title":"Nat Rev Microbiol"},{"key":"B4","doi-asserted-by":"publisher","first-page":"649","DOI":"10.1136\/pgmj.2006.047340corr1","article-title":"Leishmaniasis","volume":"83","author":"Piscopo","year":"2006","journal-title":"Postgrad Med J"},{"key":"B5","doi-asserted-by":"publisher","first-page":"9375","DOI":"10.1073\/pnas.0703678104","article-title":"Evolutionary and geographical history of the Leishmania donovani complex with a revision of current taxonomy","volume":"104","author":"Lukes","year":"2007","journal-title":"Proc Natl Acad Sci U S A"},{"key":"B6","doi-asserted-by":"publisher","first-page":"1922","DOI":"10.1111\/j.1462-5822.2006.00758.x","article-title":"Leishmania donovani lipophosphoglycan blocks NADPH oxidase assembly at the phagosome membrane","volume":"8","author":"Lodge","year":"2006","journal-title":"Cell Microbiol"},{"issue":"2","key":"B7","doi-asserted-by":"publisher","first-page":"177","DOI":"10.4103\/0974-777X.62881","article-title":"Leishmaniasis vaccine: where are we today?","volume":"2","author":"Kedzierski","year":"2010","journal-title":"J Glob Infect Dis"},{"key":"B8","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1128\/CMR.19.1.111-126.2006","article-title":"Drug resistance in leishmaniasis","volume":"19","author":"Croft","year":"2006","journal-title":"Clin Microbiol Rev"},{"issue":"2","key":"B9","doi-asserted-by":"publisher","first-page":"85","DOI":"10.7555\/JBR.27.20120064","article-title":"Development of Leishmania vaccines: predicting the future from past and present experience","volume":"27","author":"Mutiso","year":"2013","journal-title":"J Biomed Res"},{"key":"B10","doi-asserted-by":"publisher","first-page":"234fs18","DOI":"10.1126\/scitranslmed.3009118","article-title":"Using humans to make a human leishmaniasis vaccine","volume":"6","author":"Kamhawi","year":"2014","journal-title":"Sci Transl Med"},{"key":"B11","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1016\/S0165-2478(98)00132-1","article-title":"T-cell response in human leishmaniasis","volume":"65","author":"Kharazmi","year":"1999","journal-title":"Immunol Lett"},{"key":"B12","doi-asserted-by":"publisher","first-page":"7064","DOI":"10.4049\/jimmunol.165.12.7064","article-title":"Immunization with a recombinant stage-regulated surface protein from Leishmania donovani induces protection against visceral leishmaniasis","volume":"165","author":"Stager","year":"2000","journal-title":"J Immunol"},{"key":"B13","doi-asserted-by":"publisher","first-page":"372","DOI":"10.1002\/prca.200780017","article-title":"Proteomic approaches for discovery of new targets for vaccine and therapeutics against visceral leishmaniasis","volume":"3","author":"Kumari","year":"2008","journal-title":"Proteomics Clin Appl"},{"issue":"24","key":"B14","doi-asserted-by":"publisher","first-page":"3265","DOI":"10.1093\/bioinformatics\/btm471","article-title":"Modeling the adaptive immune system: predictions and simulations","volume":"23","author":"Lundegaard","year":"2007","journal-title":"Bioinformatics"},{"key":"B15","doi-asserted-by":"publisher","first-page":"1709","DOI":"10.1016\/j.vaccine.2008.01.023","article-title":"Vaccines for leishmaniasis in the fore coming 25 years","volume":"26","author":"Palatnik de Sousa","year":"2008","journal-title":"Vaccine"},{"key":"B16","first-page":"414","article-title":"The history of leishmaniasis","volume-title":"Protozoal Diseases","author":"Bray","year":"2000"},{"key":"B17","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1128\/CMR.14.2.229-243.2001","article-title":"Leishmaniasis: current status of vaccine development","volume":"14","author":"Handman","year":"2001","journal-title":"Clin Microbiol Rev"},{"key":"B18","first-page":"106","article-title":"Segunda nota sobre a vacinacao preventiva na leishmaniose tegumentar Americana com leptomones mortas","volume":"19","author":"Pessoa","year":"1941","journal-title":"Rev Paul Med"},{"key":"B19","first-page":"141","article-title":"Enseaio sobre vacinacao preventive na leishmaniose tegumentar americana com germenes mortos","volume":"6","author":"Pessoa","year":"1941","journal-title":"Arq Hig Saude Publ"},{"issue":"1","key":"B20","first-page":"1","article-title":"Leishmania vaccines updates","volume":"5","author":"Basyoni","year":"2012","journal-title":"PUJ"},{"key":"B21","doi-asserted-by":"crossref","first-page":"826","DOI":"10.4269\/ajtmh.1994.51.826","article-title":"Endemic kala-azar in eastern Sudan: a longitudinal study on the incidence of clinical and subclinical infection and post-kala-azar dermal leishmaniasis","volume":"51","author":"Zijlstra","year":"1994","journal-title":"Am J Trop Med Hyg"},{"key":"B22","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1017\/S0031182097002175","article-title":"Vaccination of langur monkeys (Presbytis entellus) against Leishmania donovani with autoclaved L. major plus BCG","volume":"116","author":"Dube","year":"1998","journal-title":"Parasitology"},{"key":"B23","doi-asserted-by":"publisher","first-page":"3485","DOI":"10.1016\/S0264-410X(01)00058-5","article-title":"Successful vaccination against Leishmania donovani infection in Indian langur using alum-precipitated autoclaved Leishmania major with BCG","volume":"19","author":"Misra","year":"2001","journal-title":"Vaccine"},{"key":"B24","doi-asserted-by":"publisher","first-page":"1565","DOI":"10.1016\/S0140-6736(00)03128-7","article-title":"Autoclaved Leishmania major vaccine for prevention of visceral leishmainiasis: a randomised, double-blind, BCG-controlled trial in Sudan","volume":"356","author":"Khalil","year":"2000","journal-title":"Lancet"},{"issue":"3","key":"B25","doi-asserted-by":"publisher","first-page":"365","DOI":"10.1016\/S0035-9203(03)90171-4","article-title":"Alum-precipitated autoclaved Leishmania major plus Bacillus Calmette-Guerrin, a candidate vaccine for visceral leishmaniasis: safety, skin-delayed type hypersensitivity response and dose finding in healthy volunteers","volume":"97","author":"Kamil","year":"2003","journal-title":"Trans R Soc Trop Med Hyg"},{"key":"B26","doi-asserted-by":"publisher","first-page":"4097","DOI":"10.1016\/j.vaccine.2004.03.058","article-title":"Double blind randomized efficacy field trial of alum precipitated autoclaved Leishmania major vaccine mixed with BCG against canine visceral leishmaniasis in Meshkin-Shahr district, I. R. Iran","volume":"22","author":"Mohebali","year":"2004","journal-title":"Vaccine"},{"key":"B27","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1016\/j.trstmh.2007.08.006","article-title":"Immunochemotherapy of persistent post-kala-azar dermal leishmaniasis: a novel approach to treatment","volume":"102","author":"Musa","year":"2008","journal-title":"Trans R Soc Trop Med Hyg"},{"key":"B28","doi-asserted-by":"publisher","first-page":"1179","DOI":"10.1016\/S0264-410X(98)00338-7","article-title":"Evaluation of the stability and immunogenicity of autoclaved and nonautoclaved preparations of a vaccine against American tegumentary leishmaniasis","volume":"17","author":"De Luca","year":"1999","journal-title":"Vaccine"},{"key":"B29","doi-asserted-by":"publisher","first-page":"6372","DOI":"10.1128\/IAI.73.10.6372-6382.2005","article-title":"Live nonpathogenic parasitic vector as a candidate vaccine against visceral leishmaniasis","volume":"73","author":"Breton","year":"2005","journal-title":"Infect Immun"},{"key":"B30","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1128\/IAI.70.1.62-68.2002","article-title":"Reduced Infectivity of a Leishmania donovani biopterin transporter genetic mutant and its use as an attenuated strain for vaccination","volume":"70","author":"Papadopoulou","year":"2002","journal-title":"Infect Immun"},{"key":"B31","doi-asserted-by":"publisher","first-page":"3161","DOI":"10.4049\/jimmunol.179.5.3161","article-title":"SIR2-deficient Leishmania infantum induces a defined IFN-\u00ce\u00b3\/IL-10 pattern that correlates with protection","volume":"179","author":"Silvestre","year":"2007","journal-title":"J Immunol"},{"key":"B32","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1016\/j.vaccine.2009.09.114","article-title":"Recombinant Leishmania tarentolae expressing the A2 virulence gene as a novel candidate vaccine against visceral leishmaniasis","volume":"28","author":"Mizbani","year":"2009","journal-title":"Vaccine"},{"issue":"5","key":"B33","doi-asserted-by":"publisher","first-page":"2138","DOI":"10.4049\/jimmunol.1202801","article-title":"Live attenuated Leishmania donovani p27 gene knockout parasites are nonpathogenic and elicit long-term protective immunity in BALB\/c mice","volume":"190","author":"Dey","year":"2013","journal-title":"J Immunol"},{"key":"B34","doi-asserted-by":"publisher","first-page":"178","DOI":"10.1002\/eji.200838389","article-title":"Photodynamic vaccination of hamsters with inducible suicidal mutants of Leishmania amazonensis elicits immunity against visceral leishmaniasis","volume":"39","author":"Kumari","year":"2009","journal-title":"Eur J Immunol"},{"key":"B35","doi-asserted-by":"publisher","first-page":"1813","DOI":"10.4049\/jimmunol.0900276","article-title":"Intracellular replication-deficient Leishmania donovani induces long lasting protective immunity against visceral leishmaniasis","volume":"183","author":"Selvapandiyan","year":"2009","journal-title":"J Immunol"},{"key":"B36","doi-asserted-by":"publisher","first-page":"1785","DOI":"10.1016\/j.vaccine.2013.01.048","article-title":"Induction of immunogenicity by live attenuated Leishmania donovani centrin deleted parasites in dogs","volume":"31","author":"Fiuza","year":"2013","journal-title":"Vaccine"},{"key":"B37","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1016\/S1674-8301(12)60002-5","article-title":"Leishmania donovani whole cell antigen delivered with adjuvants protects against visceral leishmaniasis in vervet monkeys (Chlorocebus aethiops)","volume":"26","author":"Mutiso","year":"2012","journal-title":"J Biomed Res"},{"key":"B38","doi-asserted-by":"crossref","first-page":"699","DOI":"10.4049\/jimmunol.144.2.699","article-title":"Characterization of two proteins from Leishmania donovani and their use for vaccination against visceral leishmaniasis","volume":"144","author":"Jaffe","year":"1990","journal-title":"J Immunol"},{"key":"B39","first-page":"547","article-title":"Experimental murine Leishmania donovani infection: immunoprotection by the fucose-mannose ligand (FML)","volume":"27","author":"Palatnik de Sousa","year":"1994","journal-title":"Braz J Med Biol Res"},{"key":"B40","first-page":"290","article-title":"The FML-vaccine (fucose-mannose ligand) protects hamsters from experimental kala-azar","volume":"46","author":"Palatnik de Sousa","year":"1994","journal-title":"J Braz Assoc Adv Sci"},{"key":"B41","doi-asserted-by":"publisher","first-page":"2554","DOI":"10.1016\/S0264-410X(99)00058-4","article-title":"Vaccination of Swiss albino mice against experimental visceral leishmaniasis with the FML antigen of Leishmania donovani","volume":"17","author":"Santos","year":"1999","journal-title":"Vaccine"},{"key":"B42","doi-asserted-by":"publisher","first-page":"2423","DOI":"10.1016\/j.vaccine.2005.11.061","article-title":"The FML-vaccine (Leishmune) against canine visceral leishmaniasis: a transmission blocking vaccine","volume":"24","author":"Saraiva","year":"2006","journal-title":"Vaccine"},{"key":"B43","doi-asserted-by":"publisher","first-page":"2825","DOI":"10.1016\/j.vaccine.2004.11.061","article-title":"Protection against experimental visceral leishmaniasis infection in dogs immunized with purified excreted secreted antigens of Leishmania infantum promastigotes","volume":"23","author":"Lemesre","year":"2005","journal-title":"Vaccine"},{"key":"B44","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1016\/j.vetimm.2008.10.309","article-title":"Effective humoral and cellular immunoprotective responses in LiESAp-MDP vaccinated protected dogs","volume":"128","author":"Bourdoiseau","year":"2009","journal-title":"Vet Immunol Immunopathol"},{"key":"B45","doi-asserted-by":"crossref","first-page":"2062","DOI":"10.1128\/IAI.63.5.2062-2069.1995","article-title":"A recombinant Leishmania chagasi antigen that stimulates cellular immune responses in infected mice","volume":"63","author":"Wilson","year":"1995","journal-title":"Infect Immun"},{"key":"B46","doi-asserted-by":"publisher","first-page":"5888","DOI":"10.1016\/j.vaccine.2008.05.095","article-title":"Protective immunity against challenge with Leishmania chagasi in beagle dogs vaccinated with recombinant A2 protein","volume":"26","author":"Fernandes","year":"2008","journal-title":"Vaccine"},{"key":"B47","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1016\/j.exppara.2008.09.019","article-title":"Vaccination with a novel recombinant Leishmania antigen plus MPL provides partial protection against L. donovani challenge in experimental model of visceral leishmaniasis","volume":"121","author":"Bhardwaj","year":"2009","journal-title":"Exp Parasitol"},{"key":"B48","doi-asserted-by":"publisher","first-page":"6417","DOI":"10.4049\/jimmunol.1102081","article-title":"Elongation factor-2, a Th1 stimulatory protein of Leishmania donovani, generates strong IFN-\u00ce\u00b3 and IL-12 response in cured Leishmania-infected patients\/hamsters and protects hamsters against Leishmania challenge","volume":"187","author":"Kushawaha","year":"2011","journal-title":"J Immunol"},{"issue":"5","key":"B49","doi-asserted-by":"publisher","first-page":"429","DOI":"10.1016\/j.ijpara.2012.02.013","article-title":"A novel recombinant Leishmania donovani p45, a partial coding region of methionine aminopeptidase, generates protective immunity by inducing a Th1 stimulatory response against experimental visceral leishmaniasis","volume":"42","author":"Gupta","year":"2012","journal-title":"Int J Parasitol"},{"key":"B50","doi-asserted-by":"publisher","first-page":"e45766","DOI":"10.1371\/journal.pone.0045766","article-title":"Leishmania donovani triose phosphate isomerase: a potential vaccine target against visceral leishmaniasis","volume":"7","author":"Kushawaha","year":"2012","journal-title":"PLoS One"},{"key":"B51","doi-asserted-by":"publisher","first-page":"e35670","DOI":"10.1371\/journal.pone.0035670","article-title":"Evaluation of Leishmania donovani protein disulfide isomerase as a potential immunogenic protein\/vaccine candidate against visceral leishmaniasis","volume":"7","author":"Kushawaha","year":"2012","journal-title":"PLoS One"},{"key":"B52","doi-asserted-by":"publisher","first-page":"851","DOI":"10.1007\/s00436-013-3716-5","article-title":"Efficacy of Leishmania donovani trypanothione reductase,identified as a potent Th1 stimulatory protein, for its immunogenicity and prophylactic potential against experimental visceral leishmaniasis","volume":"113","author":"Khare","year":"2014","journal-title":"Parasitol Res"},{"issue":"1","key":"B53","doi-asserted-by":"publisher","first-page":"e86073","DOI":"10.1371\/journal.pone.0086073","article-title":"Characterization of glycolytic enzymes \u00e2\u20ac\u201c rAldolase and rEnolase of Leishmania donovani, identified as Th1 stimulatory proteins, for their immunogenicity and immunoprophylactic efficacies against experimental visceral leishmaniasis","volume":"9","author":"Gupta","year":"2014","journal-title":"PLoS One"},{"key":"B54","doi-asserted-by":"publisher","first-page":"967","DOI":"10.1016\/j.micinf.2010.06.008","article-title":"Vaccination with the Leishmania infantum ribosomal proteins induces protection in BALB\/c mice against Leishmania chagasi and Leishmania amazonensis challenge","volume":"12","author":"Chavez-Fumagalli","year":"2010","journal-title":"Microbes Infect"},{"issue":"3","key":"B55","doi-asserted-by":"publisher","first-page":"e2148","DOI":"10.1371\/journal.pntd.0002148","article-title":"Antigenicity and protective efficacy of a Leishmania amastigote specific protein, member of the super-oxygenase family, against visceral leishmaniasis","volume":"7","author":"Martins","year":"2013","journal-title":"PLoS Negl Trop Dis"},{"key":"B56","doi-asserted-by":"publisher","first-page":"660","DOI":"10.1128\/CVI.00358-09","article-title":"In situ immunolocalization and stage-dependent expression of a secretory serine protease in Leishmania donovani and its role as a vaccine candidate","volume":"17","author":"Choudhury","year":"2010","journal-title":"Clin Vaccine Immunol"},{"key":"B57","doi-asserted-by":"publisher","first-page":"4223","DOI":"10.1016\/j.vaccine.2007.02.083","article-title":"Long-lasting protection against canine visceral leishmaniasis using the LiESAp-MDP vaccine in endemic areas of France: double-blind randomised efficacy field trial","volume":"25","author":"Lemesre","year":"2007","journal-title":"Vaccine"},{"key":"B58","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/S0165-2427(02)00315-X","article-title":"A Leishmania infantum multi-component antigenic protein mixed with live BCG confers protection to dogs experimentally infected with L. infantum","volume":"92","author":"Molano","year":"2003","journal-title":"Vet Immunol Immunopathol"},{"key":"B59","doi-asserted-by":"publisher","first-page":"283","DOI":"10.1111\/j.0141-9838.2004.00711.x","article-title":"Adjuvant guided polarization of the immune humoral response against a protective multicomponent antigenic protein (Q) from Leishmania infantum. A CpG +Q mix protects Balb\/c mice from infection","volume":"26","author":"Parody","year":"2004","journal-title":"Parasite Immunol"},{"key":"B60","doi-asserted-by":"publisher","first-page":"5245","DOI":"10.1016\/j.vaccine.2005.07.001","article-title":"Failure of a multi-subunit recombinant Leishmania vaccine (MML) to protect dogs from Leishmania infantum infection and to prevent disease progression in infected animals","volume":"23","author":"Gradoni","year":"2005","journal-title":"Vaccine"},{"key":"B61","doi-asserted-by":"publisher","first-page":"4648","DOI":"10.1128\/IAI.00394-07","article-title":"Leish-111f, a recombinant polyprotein vaccine that protects against visceral leishmaniasis by elicitation of CD4+ T cells","volume":"75","author":"Coler","year":"2007","journal-title":"Infect Immun"},{"key":"B62","doi-asserted-by":"publisher","first-page":"3333","DOI":"10.1016\/j.vaccine.2010.02.089","article-title":"Treatment of canine visceral leishmaniasis by the vaccine Leish-111f +MPL-SE","volume":"28","author":"Trigo","year":"2010","journal-title":"Vaccine"},{"key":"B63","doi-asserted-by":"publisher","first-page":"7036","DOI":"10.1016\/j.vaccine.2009.09.066","article-title":"Optimized subunit vaccine protects against experimental leishmaniasis","volume":"23","author":"Bertholet","year":"2009","journal-title":"Vaccine"},{"key":"B64","doi-asserted-by":"publisher","first-page":"1118","DOI":"10.1128\/CVI.05024-11","article-title":"KSAC, the first defined polyprotein vaccine candidate for visceral leishmaniasis","volume":"18","author":"Goto","year":"2011","journal-title":"Clin Vaccine Immunol"},{"key":"B65","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1016\/S0264-410X(01)00322-X","article-title":"Immunization with A2 protein results in a mixed Th1\/Th2 and a humoral response which protects mice against Leishmania donovani infections","volume":"20","author":"Ghosh","year":"2001","journal-title":"Vaccine"},{"key":"B66","doi-asserted-by":"publisher","first-page":"4719","DOI":"10.1128\/IAI.69.8.4719-4725.2001","article-title":"Leishmania donovani p36 (LACK) DNA vaccine is highly immunogenic but not protective against experimental visceral leishmaniasis","volume":"69","author":"Melby","year":"2001","journal-title":"Infect Immun"},{"key":"B67","doi-asserted-by":"publisher","first-page":"1292","DOI":"10.1016\/S0264-410X(02)00352-3","article-title":"Vaccination with DNA encoding ORFF antigen confers protective immunity in mice infected with Leishmania donovani","volume":"21","author":"Sukumaran","year":"2003","journal-title":"Vaccine"},{"key":"B68","doi-asserted-by":"publisher","first-page":"7160","DOI":"10.4049\/jimmunol.174.11.7160","article-title":"Kinetoplastid membrane protein-11 DNA vaccination induces complete protection against both pentavalent antimonial sensitive and resistant strains of Leishmania donovani that correlates with inducible nitric oxide synthase activity and IL-4 generation: evidence for mixed Th1- and Th2-like responses in visceral leishmaniasis","volume":"174","author":"Basu","year":"2005","journal-title":"J Immunol"},{"key":"B69","doi-asserted-by":"publisher","first-page":"1306","DOI":"10.1016\/j.vaccine.2008.12.053","article-title":"KMP-11 DNA immunization significantly protects against L. donovani infection but requires exogenous IL-12 as an adjuvant for comparable protection against L. major","volume":"27","author":"Bhaumik","year":"2009","journal-title":"Vaccine"},{"key":"B70","doi-asserted-by":"publisher","first-page":"1928","DOI":"10.1016\/j.vaccine.2005.10.052","article-title":"Immunogenicity of a multicomponent DNA vaccine against visceral leishmaniasis in dogs","volume":"24","author":"Saldarriaga","year":"2006","journal-title":"Vaccine"},{"key":"B71","doi-asserted-by":"publisher","first-page":"4502","DOI":"10.1016\/j.vaccine.2007.03.014","article-title":"DNA vaccination against the parasite enzyme gamma glutamyl cysteine synthetase confers protection against Leishmania donovani infection","volume":"25","author":"Carter","year":"2007","journal-title":"Vaccine"},{"key":"B72","doi-asserted-by":"publisher","first-page":"7719","DOI":"10.4049\/jimmunol.0900132","article-title":"Ubiquitin conjugation of open reading frame F DNA vaccine leads to enhanced cell-mediated immune response and induces protection against both antimony-susceptible and -resistant strains of Leishmania donovani","volume":"183","author":"Sharma","year":"2009","journal-title":"J Immunol"},{"key":"B73","doi-asserted-by":"publisher","first-page":"470","DOI":"10.4049\/jimmunol.0900265","article-title":"Immunization with the DNA-encoding N-terminal domain of proteophosphoglycan of Leishmania donovani generates Th1-type immunoprotective response against experimental visceral leishmaniasis","volume":"183","author":"Samant","year":"2009","journal-title":"J Immunol"},{"issue":"202","key":"B74","doi-asserted-by":"publisher","first-page":"202ra121","DOI":"10.1126\/scitranslmed.3006406","article-title":"Vaccination with Leishmania hemoglobin receptor-encoding DNA protects against visceral leishmaniasis","volume":"5","author":"Guha","year":"2013","journal-title":"Sci Transl Med"},{"issue":"1","key":"B75","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1007\/s00436-005-0008-8","article-title":"Intramuscular immunization with p36(LACK) DNA vaccine induces IFN-\u00ce\u00b3 production but does not protect BALB\/c mice against Leishmania chagasi intravenous challenge","volume":"98","author":"Marques-da-Silva","year":"2005","journal-title":"Parasitol Res"},{"key":"B76","doi-asserted-by":"publisher","first-page":"1701","DOI":"10.1016\/S0264-410X(00)00398-4","article-title":"Immunisation with DNA encoding Leishmania infantum protein papLe22 decreases the frequency of parasitemic episodes in infected hamsters","volume":"19","author":"Fragaki","year":"2001","journal-title":"Vaccine"},{"issue":"12","key":"B77","doi-asserted-by":"publisher","first-page":"2168","DOI":"10.1016\/j.vaccine.2006.11.060","article-title":"Intranasal delivery of naked DNA encoding the LACK antigen leads to protective immunity against visceral leishmaniasis in mice","volume":"25","author":"Gomes","year":"2007","journal-title":"Vaccine"},{"key":"B78","doi-asserted-by":"publisher","first-page":"2537","DOI":"10.1016\/j.vaccine.2008.03.003","article-title":"Immunization strategies against visceral leishmaniasis with the nucleosomal histones of Leishmania infantum encoded in DNA vaccine or pulsed in dendritic cells","volume":"26","author":"Carrion","year":"2008","journal-title":"Vaccine"},{"issue":"2","key":"B79","doi-asserted-by":"publisher","first-page":"812","DOI":"10.1128\/IAI.73.2.812-819.2005","article-title":"Cross-protective efficacy of a prophylactic Leishmania donovani DNA vaccine against visceral and cutaneous murine leishmaniasis","volume":"73","author":"Aguilar-Be","year":"2005","journal-title":"Infect Immun"},{"key":"B80","doi-asserted-by":"publisher","first-page":"4863","DOI":"10.1016\/j.vaccine.2006.03.005","article-title":"Immunotherapy against visceral leishmaniasis with the nucleoside hydrolase DNA vaccine of Leishmania donovani","volume":"24","author":"Gamboa-Leon","year":"2006","journal-title":"Vaccine"},{"key":"B81","doi-asserted-by":"publisher","first-page":"1070","DOI":"10.1016\/j.micinf.2007.05.012","article-title":"Evaluation of immune responses and protection induced by A2 and nucleoside hydrolase (NH) DNA vaccines against Leishmania chagasi and Leishmania amazonensis experimental infections","volume":"9","author":"Zanin","year":"2007","journal-title":"Microbes Infect"},{"key":"B82","doi-asserted-by":"publisher","first-page":"2130","DOI":"10.1086\/430348","article-title":"A heterologous prime-boost vaccination regimen using ORFF DNA and recombinant ORFF protein confers protective immunity against experimental visceral leishmaniasis","volume":"191","author":"Tewary","year":"2005","journal-title":"J Infect Dis"},{"key":"B83","doi-asserted-by":"publisher","first-page":"e14644","DOI":"10.1371\/journal.pone.0014644","article-title":"Potency, efficacy and durability of DNA\/DNA, DNA\/protein and protein\/protein based vaccination using GP63 against Leishmania donovani in BALB\/c mice","volume":"6","author":"Mazumder","year":"2011","journal-title":"PLoS One"},{"key":"B84","doi-asserted-by":"publisher","first-page":"5286","DOI":"10.1128\/IAI.73.8.5286-5289.2005","article-title":"Heterologous prime \u00e2\u20ac\u201c boost vaccination with the LACK antigen protects against murine visceral leishmaniasis","volume":"73","author":"Dondji","year":"2005","journal-title":"Infect Immun"},{"key":"B85","doi-asserted-by":"publisher","first-page":"2474","DOI":"10.1016\/S0264-410X(03)00032-X","article-title":"Protection in dogs against visceral leishmaniasis caused by Leishmania infantum is achieved by immunization with a heterologous prime-boost regime using DNA vaccine and vaccinia recombinant vectors expressing LACK","volume":"21","author":"Ramiro","year":"2003","journal-title":"Vaccine"},{"key":"B86","doi-asserted-by":"publisher","first-page":"2169","DOI":"10.1016\/j.vaccine.2005.11.011","article-title":"Prime boost vaccination using cysteine proteinases type I and II of Leishmania infantum confers protective immunity in murine visceral leishmaniasis","volume":"24","author":"Rafati","year":"2006","journal-title":"Vaccine"},{"issue":"28","key":"B87","doi-asserted-by":"publisher","first-page":"3716","DOI":"10.1016\/j.vaccine.2005.02.009","article-title":"Protective vaccination against experimental canine visceral leishmaniasis using a combination of DNA and protein immunization with cysteine proteinases type I and II of L. infantum","volume":"23","author":"Rafati","year":"2005","journal-title":"Vaccine"},{"key":"B88","doi-asserted-by":"publisher","first-page":"6697","DOI":"10.1128\/IAI.70.12.6697-6706.2002","article-title":"Characterization of Leishmania donovani antigens encapsulated in liposomes that induce protective immunity in BALB\/c mice","volume":"70","author":"Afrin","year":"2002","journal-title":"Infect Immun"},{"key":"B89","doi-asserted-by":"publisher","first-page":"8771","DOI":"10.1016\/j.vaccine.2007.10.028","article-title":"Non-coding pDNA bearing immunostimulatory sequences co-entrapped with Leishmania antigens in cationic liposomes elicits almost complete protection against experimental visceral leishmaniasis in BALB\/c mice","volume":"25","author":"Mazumder","year":"2007","journal-title":"Vaccine"},{"key":"B90","doi-asserted-by":"publisher","first-page":"1003","DOI":"10.1128\/IAI.00611-07","article-title":"GP63 in stable cationic liposomes confers sustained vaccine immunity to susceptible BALB\/c mice infected with Leishmania donovani","volume":"76","author":"Bhowmick","year":"2008","journal-title":"Infect Immun"},{"key":"B91","doi-asserted-by":"publisher","first-page":"5086","DOI":"10.1016\/j.vaccine.2012.05.075","article-title":"Vaccination with Leishmania histone H1-pulsed dendritic cells confers protection in murine visceral leishmaniasis","volume":"30","author":"Agallou","year":"2012","journal-title":"Vaccine"},{"key":"B92","doi-asserted-by":"publisher","first-page":"7845","DOI":"10.1073\/pnas.0712153105","article-title":"Immunity to a salivary protein of a sandfly vector protects against the fatal outcome of visceral leishmaniasis in a hamster model","volume":"105","author":"Gomes","year":"2008","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"5","key":"B93","doi-asserted-by":"publisher","first-page":"e1000441","DOI":"10.1371\/journal.ppat.1000441","article-title":"Sand fly salivary proteins induce strong cellular immunity in a natural reservoir of visceral leishmaniasis with adverse consequences for Leishmania","volume":"5","author":"Collin","year":"2009","journal-title":"PLoS Pathog"},{"issue":"7","key":"B94","doi-asserted-by":"publisher","first-page":"341","DOI":"10.1016\/j.pt.2010.04.005","article-title":"Immunity to Leishmania and the rational search for vaccines against canine leishmaniasis","volume":"26","author":"Reis","year":"2010","journal-title":"Trends Parasitol"},{"key":"B95","doi-asserted-by":"publisher","first-page":"244","DOI":"10.1016\/j.pt.2005.03.006","article-title":"Second-generation vaccines against leishmaniasis","volume":"21","author":"Coler","year":"2005","journal-title":"Trends Parasitol"},{"key":"B96","doi-asserted-by":"publisher","first-page":"4103","DOI":"10.1128\/IAI.69.6.4103-4108.2001","article-title":"Protection against cutaneous leishmaniasis induced by recombinant antigens in murine and nonhuman primate models of the human disease","volume":"69","author":"Campos-Neto","year":"2001","journal-title":"Infect Immun"},{"key":"B97","doi-asserted-by":"publisher","first-page":"6759","DOI":"10.1016\/j.vaccine.2008.09.085","article-title":"First generation leishmaniasis vaccines: a review of field efficacy trials","volume":"26","author":"Noazin","year":"2008","journal-title":"Vaccine"},{"key":"B98","doi-asserted-by":"publisher","first-page":"604","DOI":"10.1038\/nrmicro2608","article-title":"Leishmaniasis: complexity at the host pathogen interface","volume":"9","author":"Kaye","year":"2011","journal-title":"Nat Rev Microbiol"},{"key":"B99","doi-asserted-by":"publisher","first-page":"e13","DOI":"10.1038\/cti.2014.4","article-title":"Vaccines to prevent leishmaniasis","volume":"3","author":"Kumar","year":"2014","journal-title":"Clin Trans Immunol"},{"key":"B100","doi-asserted-by":"publisher","first-page":"4813","DOI":"10.1016\/j.vaccine.2008.06.102","article-title":"Induction of Th1-type cellular responses in cured\/exposed Leishmania-infected patients and hamsters against polyproteins of soluble Leishmania donovani promastigotes ranging from 89.9 to 97.1kDa","volume":"26","author":"Kumari","year":"2008","journal-title":"Vaccine"},{"key":"B101","doi-asserted-by":"publisher","first-page":"5700","DOI":"10.1016\/j.vaccine.2008.08.021","article-title":"Th1-stimulatory polyproteins of soluble Leishmania donovani promastigotes ranging from 89.9 to 97.1kDa offers long-lasting protection against experimental visceral leishmaniasis","volume":"26","author":"Kumari","year":"2008","journal-title":"Vaccine"},{"key":"B102","first-page":"14","article-title":"An improved manufacturing process for a recombinant polyprotein vaccine","author":"Vedvick","year":"2008","journal-title":"Biopharm Inter"},{"key":"B103","doi-asserted-by":"publisher","first-page":"234ra56","DOI":"10.1126\/scitranslmed.3008222","article-title":"Modular multiantigen T cell epitope-enriched DNA vaccine against human leishmaniasis","volume":"6","author":"Das","year":"2014","journal-title":"Sci Transl Med"},{"key":"B104","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1016\/j.jconrel.2009.09.018","article-title":"Comparison of liposome based antigen delivery systems for protection against Leishmania donovani","volume":"141","author":"Bhowmick","year":"2010","journal-title":"J Control Release"},{"issue":"3","key":"B105","doi-asserted-by":"publisher","first-page":"331","DOI":"10.1084\/jem.194.3.331","article-title":"Toward a defined anti-Leishmania vaccine targeting vector antigens: characterization of a protective salivary protein","volume":"194","author":"Valenzuela","year":"2001","journal-title":"J Exp Med"},{"key":"B106","doi-asserted-by":"publisher","first-page":"5226","DOI":"10.4049\/jimmunol.167.9.5226","article-title":"Sandfly maxadilan exacerbates infection with Leishmania major and vaccinating against it protects against L. major infection","volume":"167","author":"Morris","year":"2001","journal-title":"J Immunol"},{"issue":"3","key":"B107","doi-asserted-by":"publisher","first-page":"154","DOI":"10.1007\/s40475-014-0024-9","article-title":"The emergence of defined subunit vaccines for the prevention of leishmaniasis","volume":"1","author":"Duthie","year":"2014","journal-title":"Curr Trop Med Rep"},{"issue":"2","key":"B108","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1007\/s00005-008-0010-9","article-title":"Live attenuated Leishmania vaccines: a potential strategic alternative","volume":"56","author":"Silvestre","year":"2008","journal-title":"Arch Immunol Ther Exp (Warsz)"},{"key":"B109","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1038\/ni1162","article-title":"Inflammatory mediators are insufficient for full dendritic cell activation and promote expansion of CD4+ T cell populations lacking helper function","volume":"6","author":"Sporri","year":"2005","journal-title":"Nat Immunol"},{"key":"B110","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1111\/j.0105-2896.2006.00400.x","article-title":"Th1 memory: implications for vaccine development","volume":"211","author":"Foulds","year":"2006","journal-title":"Immunol Rev"},{"issue":"22","key":"B111","doi-asserted-by":"publisher","first-page":"10267","DOI":"10.1073\/pnas.92.22.10267","article-title":"Development of a safe live Leishmania vaccine line by gene replacement","volume":"92","author":"Titus","year":"1995","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"24","key":"B112","doi-asserted-by":"publisher","first-page":"25703","DOI":"10.1074\/jbc.M402794200","article-title":"Centrin gene disruption impairs stage-specific basal body duplication and cell cycle progression in Leishmania","volume":"279","author":"Selvapandiyan","year":"2004","journal-title":"J Bio Chem"},{"issue":"1","key":"B113","doi-asserted-by":"publisher","first-page":"27","DOI":"10.4161\/hv.6.1.9601","article-title":"The past decade in malaria synthetic peptide vaccine clinical trials","volume":"6","author":"Nardin","year":"2010","journal-title":"Hum Vaccin"},{"key":"B114","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1186\/1756-3305-6-125","article-title":"Screening and identification of novel B cell epitopes of Toxoplasma gondii SAG1","volume":"6","author":"Wang","year":"2013","journal-title":"Parasit Vectors"},{"key":"B115","doi-asserted-by":"publisher","first-page":"3525","DOI":"10.1016\/j.vaccine.2014.04.026","article-title":"A synthetic peptide from Trypanosoma cruzi mucin-like associated surface protein as candidate for a vaccine against Chagas disease","volume":"32","author":"Serna","year":"2014","journal-title":"Vaccine"},{"key":"B116","doi-asserted-by":"publisher","first-page":"645","DOI":"10.1084\/jem.172.2.645","article-title":"Immunoprotective Leishmania major synthetic T-cell epitopes","volume":"172","author":"Jardim","year":"1990","journal-title":"J Exp Med"},{"key":"B117","first-page":"3","article-title":"Identification and characterization of host-protective T-cell epitopes of a major surface glycoprotein (GP63) from Leishmania major","volume":"72","author":"Yang","year":"1991","journal-title":"J Immunol"},{"issue":"9","key":"B118","doi-asserted-by":"publisher","first-page":"923","DOI":"10.1016\/0264-410X(95)00245-V","article-title":"Effective immunization of mice against cutaneous leishmaniasis using an intrinsically adjuvanted synthetic lipopeptide vaccine","volume":"14","author":"Frankenburg","year":"1996","journal-title":"Vaccine"},{"key":"B119","doi-asserted-by":"publisher","first-page":"1298","DOI":"10.1016\/S0264-410X(98)00363-6","article-title":"Long-term protection of mice against Leishmania major with a synthetic peptide vaccine","volume":"17","author":"Spitzer","year":"1999","journal-title":"Vaccine"},{"issue":"2","key":"B120","first-page":"273","article-title":"Immunogenicity of HLA-DR1 restricted peptides derived from Leishmania major GP63 using FVB\/N-DR1 transgenic mouse model","volume":"8","author":"Rezvan","year":"2013","journal-title":"Iran J Parasitol"},{"issue":"4","key":"B121","first-page":"27","article-title":"Immunogenicity of MHC class I peptides derived from Leishmania mexicana GP63 in HLA-A2.1 transgenic (HHDII) and BALB\/C mouse models","volume":"7","author":"Rezvan","year":"2012","journal-title":"Iran J Parasitol"},{"issue":"12","key":"B122","doi-asserted-by":"publisher","first-page":"1769","DOI":"10.4161\/hv.21881","article-title":"Immunogenicity and immune modulatory effects of in silico predicted L. donovani candidate peptide vaccines","volume":"8","author":"Elfaki","year":"2012","journal-title":"Hum Vaccin Immunother"},{"key":"B123","doi-asserted-by":"publisher","first-page":"1373","DOI":"10.1086\/513439","article-title":"HLA class I-restricted T cell epitopes of the kinetoplastid membrane protein-11 presented by Leishmania donovani-infected human macrophages","volume":"195","author":"Basu","year":"2007","journal-title":"J Infect Dis"},{"key":"B124","doi-asserted-by":"publisher","first-page":"4585","DOI":"10.1016\/j.vaccine.2008.05.091","article-title":"Epitope mapping and protective immunity elicited by adenovirus expressing the Leishmania amastigote specific A2 antigen: correlation with IFN-\u00ce\u00b3 and cytolytic activity by CD8+ T cells","volume":"26","author":"Resende","year":"2008","journal-title":"Vaccine"},{"issue":"9","key":"B125","doi-asserted-by":"publisher","first-page":"e1295","DOI":"10.1371\/journal.pntd.0001295","article-title":"In silico analysis of six known Leishmania major antigens and in vitro evaluation of specific epitopes eliciting HLA-A2 restricted CD8 T cell response","volume":"5","author":"Seyed","year":"2011","journal-title":"PLoS Negl Trop Dis"},{"key":"B126","doi-asserted-by":"publisher","first-page":"341","DOI":"10.1590\/S0074-02762010000300018","article-title":"Kinetoplastid membrane protein-11 is present in promastigotes and amastigotes of Leishmania amazonensis and its surface expression increases during metacyclogenesis","volume":"105","author":"Matos","year":"2010","journal-title":"Mem Inst Oswaldo Cruz"},{"key":"B127","doi-asserted-by":"crossref","first-page":"2975","DOI":"10.1128\/MCB.14.5.2975","article-title":"Developmental gene expression in Leishmania donovani: differential cloning and analysis of an amastigote-stage-specific gene","volume":"14","author":"Charest","year":"1994","journal-title":"Mol Cell Biol"},{"key":"B128","doi-asserted-by":"publisher","first-page":"268","DOI":"10.3389\/fimmu.2014.00268","article-title":"Experimental validation of multi-epitope peptides including promising MHC class I- and II-restricted epitopes of four known Leishmania infantum proteins","volume":"5","author":"Agallou","year":"2014","journal-title":"Front Immunol"}],"container-title":["Frontiers in Immunology"],"original-title":[],"deposited":{"date-parts":[[2023,7,16]],"date-time":"2023-07-16T05:30:47Z","timestamp":1689485447000},"score":1,"resource":{"primary":{"URL":"http:\/\/journal.frontiersin.org\/article\/10.3389\/fimmu.2014.00380\/abstract"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,8,22]]},"references-count":128,"URL":"https:\/\/doi.org\/10.3389\/fimmu.2014.00380","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2014,8,22]]}}}